Authors: DiNicolantonio JJ, Barroso-Aranda J, McCarty MF
PMID: 33875563 PMCID: PMC8057070 DOI: 10.1136/openhrt-2021-001655
Abstract
Ivermectin, a drug commonly used to treat a range of parasitic infections, has been shown to halve the mortality elicited by a fatal dose of lipopolysaccharide in mice, in an oral dose (4 mg/kg) that can be extrapolated to 2–4 times the standard clinical dose in humans (0.2 mg/kg).It has been suggested that this phenomenon is highly pertinent to the clinical utility of ivermectin in the cytokine storm phase of COVID-19, which has been documented in a number of clinical studies.A meta-analysis of 18 clinical studies to date examining the impact of ivermectin therapy in hospitalised COVID-19 patients has observed a roughly 68% reduction in mortality associated with its usage.
Keywords: COVID-19; cardiomyopathy; electronic health records; hypertrophic.
